In mammals, the developing reproductive tract primordium of male and female fetuses consists of the Wolffian duct and the Müllerian duct (MD), two epithelial tube pairs surrounded by mesenchyme. During male development, mesenchyme-epithelia interactions mediate MD regression to prevent its development into a uterus, oviduct and upper vagina. It is well established that transforming growth factor-beta family member anti-Müllerian hormone (AMH) secreted from the fetal testis and its type 1 and 2 receptors expressed in MD mesenchyme regulate MD regression. However, little is known about the molecular network regulating downstream actions of AMH signaling. To identify potential AMH-induced genes and regulatory networks controlling MD regression in a global non-biased manner, we examined transcriptome differences in MD mesenchyme between males (AMH signaling on) and females (AMH signaling off) by RNA-Seq analysis of purified fetal MD mesenchymal cells. This analysis found 82 genes up-regulated in males during MD regression and identified Osterix (Osx)/Sp7, a key transcriptional regulator of osteoblast differentiation and bone formation, as a novel downstream effector of AMH signaling during MD regression. Osx/OSX was expressed in a male-specific pattern in MD mesenchyme during MD regression. OSX expression was lost in mutant males without AMH signaling. In addition, transgenic mice ectopically expressing human AMH in females induced a male pattern of Osx expression. Together these results indicate that AMH signaling is necessary and sufficient for Osx expression in the MD mesenchyme. In addition, MD regression was delayed in Osx null males, identifying Osx as a new factor that regulates MD regression.
Introduction
In mammals, the Wolffian ducts (WD) differentiate into the male epididymides, vas deferens and seminal vesicles, whereas the Müllerian ducts (MD) develop into the female oviducts, uterus and upper vagina. Reproductive tract differentiation in amniotes is unique because initially both WD and MD are generated in the embryo independent of genetic sex. Sex-specific signaling results in loss of the WD in females and regression of the MD in males (1, 2) . MD regression requires transforming growth factor-β family member AMH secreted from the Sertoli cells of the fetal testis and its type 1 and 2 receptors present in MD mesenchyme (3) (4) (5) (6) (7) . Following AMH binding, AMH type 2 receptor (AMHR2) recruits a type 1 receptor into a heteromeric complex. Within the complex AMHR2 trans-phosphorylates and activates the type 1 receptor kinase. This activation results in the phosphorylation of an R-Smad and formation of an R-SMAD/SMAD-4 complex that translocates into the nucleus to transcriptionally activate AMH signaling pathway target genes. Mullen 4 AMH type 1 receptors AVCR2 and BMPR1A, and AMH R-Smad effectors (SMAD1, SMAD5 and SMAD8) function redundantly for MD regression and are shared with the bone morphogenetic protein (BMP) pathway (8, 9) .
While the upstream components (AMH, Type 1 & 2 receptors and R-Smads) of AMH signaling are well known, the downstream transcriptional effectors of AMH signaling are still largely unidentified. To date, only the WNT pathway effector β-catenin (Ctnnb1) has been shown to be required for AMH-induced MD regression in vivo (10) . The requirement of Ctnnb1 for MD regression suggests WNT signaling is important for the downstream actions of AMH during MD regression in males. However candidate gene approaches have failed to identify an individual WNT, WNT effector or WNT regulator whose in vivo loss blocks MD regression (10) (11) (12) . Because of the limited success of candidate gene approaches in uncovering AMH signaling effectors, in the current study we undertook a non-biased global approach using next generation transcriptome sequencing. To elucidate potential gene networks and novel AMH signaling targets, we used RNA-Seq analysis of YFP (yellow fluorescent protein)-positive MD mesenchymal cells flow sorted from embryonic day (E) 14.5 Amhr2 Cre/+ ; R26R yfp/+ reproductive tracts to identify transcriptome differences between males and females during regression. This analysis identified Osterix (Osx)/Sp7 as a downstream effector of AMH signaling during MD regression. Our results indicate that AMH signaling is necessary and sufficient for Osx expression in the MD mesenchyme and Osx regulates the timing of MD regression.
Results

Transcriptome analysis identifies candidate genes upregulated in male MD mesenchyme during regression
During embryogenesis, Amhr2 is expressed in the MD mesenchyme of male and female fetuses, but Amh is only expressed in males. Thus, the AMH signaling pathway is only active in male fetuses. To isolate male and female MD mesenchymal cells, Amhr2-Cre mice, which express Cre recombinase in the MD mesenchyme and somatic cells of the gonad, were bred to R26R-YFP reporter mice. E14.5 was chosen for this analysis because AMH has been expressed for 2 days in males, there are changes in the MD mesenchyme and MD epithelium, but no breaks or gaps in the MD have occurred. Mice carrying the Cre and YFP alleles were identified by fluorescence and sex was determined by gross morphology of the gonad using a dissecting microscope. The mesonephros/gonad complex was isolated and the gonads removed. Two or more mesonephroi were pooled and digested in trypsin and the resulting single cell suspensions were then sorted for YFP + cells using FACS ( Fig. 1A-C) . cDNA libraries were generated from three biological replicates each for male and female. Indexed libraries were pooled and sequenced on the Illumina HiSeq2000 platform ( Fig. 1D) . ~20 million paired end 76 base pair reads were obtained for each library, of which ~70% mapped to at least one location in the mouse reference genome build NCBIM37. Mapped mouse RNA-seq data were then subjected to differential expression analysis, using Cufflinks (13) and DESeq (14) . Genes with significant differential expression were then further parsed by removing genes with fragments per kilobase of exon per million reads mapped (FPKM) at or below those for Amh in males, a gene known to be expressed at low levels in MD mesenchyme (15) . These analyses revealed 82 genes that were significantly upregulated in males versus females during MD regression ( Table 1) . IPA analysis predicted both BMP2 and BMP4 as Mullen 6 upstream activators (data not shown). This is consistent with activation by the AMH signaling pathway because it shares components of the BMP signaling pathway, including type 1 receptors and R-SMADs. In the IPA analysis, Osx was in our gene list, predicting BMP as an upstream activator for our dataset. This suggested Osx as a potential downstream effector of AMH signaling and led us to analyze Osx expression and function during MD regression.
Osterix is expressed only in male MD mesenchyme during AMH-induced MD regression
OSTERIX (OSX) is a C2H2-type zinc finger transcription factor first cloned in a screen of C2C12 cells induced by BMP2 to differentiate into osteoblasts. Osx is required for osteoblast differentiation and bone formation (16) . However, to our knowledge this is the first study to identify a role for Osx during reproductive tract development. Using in situ hybridization we found that Osx transcripts are localized specifically in the male MD mesenchyme at E14.5 ( Fig. 2A, B) .
To determine whether the OSX protein followed a similar dynamic, we assayed OSX via immunofluorescence and found that OSX is expressed only in male MD mesenchyme at E14.5 indicating a sexually dimorphic expression pattern ( Fig. 2C, D) . This analysis was confirmed by the GUDMAP database (http://www.gudmap.org) wherein Osx expression in the MD has a malespecific pattern (17) .
Previously, we generated an Osx-lacZ (Z) null allele in mice that originally demonstrated that Osx is required for osteoblast differentiation (16) . Osx-lacZ expresses beta-galactosidase from the endogenous Osx locus and was used to temporally and spatially map expression of Osx during MD regression. Whole mount beta-galactosidase staining of E13.5 Osx Z /+ reproductive tracts showed no expression in either males or females (data not shown). Expression of Osx Z /+ begins at around E13.75 in male MD mesenchyme and robust expression throughout the length of the MD is present by E14.5 (Fig. 3F, G) . This temporal expression pattern is consistent with activation of Osx expression by the AMH signaling pathway. While Amh transcripts are present in the testis as early as E11.5 in mouse, initiation of AMH signaling in the MD follows expression of Amhr2 in the MD mesenchyme beginning at ~E13.25 (18, 19) . No expression is detected in the female reproductive tract at any time points examined ( Fig. 3A-E) . In males, Osx Z /+ expression is subsequently lost as the MD regresses ( Fig. 3 H-J) . The expression patterns of endogenous OSX and Osx-lacZ suggested that Osx expression in the MD mesenchyme is mediated by the AMH signaling pathway.
AMH signaling is necessary and sufficient for OSX/Osterix expression in MD mesenchyme
To determine if AMH signaling is required for Osx expression in the male MD mesenchyme, we examined OSX expression in E14.5 Amhr2 Z/Cre males. Amhr2 Z/Cre is a functional Amhr2 null genotype and therefore lacks AMH signaling, leading to female reproductive tract development in mutant males (18, 20) . While OSX protein can be detected in the MD mesenchyme of wild-type males at E14.5, no detectable OSX is present in Amhr2 Z/Cre males ( Fig. 4A, B) . The ability of AMH signaling alone to activate Osx expression was tested using our MT-hAMH transgenic mouse model. The MT-hAMH mouse broadly expresses human AMH, causing MD regression in females (5) . Osx-lacZ is not expressed in E14.5 Osx Z/+ females but is induced in the MD mesenchyme of Osx Z/+ ; MT-hAMH females ( Fig. 4C-F) . These results indicate that activation of the AMH signaling pathway is necessary and sufficient to initiate expression of Osx/OSX in the MD mesenchyme during reproductive tract differentiation.
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Beta-catenin is not required for OSX expression in MD mesenchyme
Beta-catenin functions downstream of AMH signaling and is required to regulate MD regression during male sex differentiation (10) . However, the downstream molecular targets of beta-catenin in the MD mesenchyme are unknown. Osx expression is upregulated by activated beta-catenin in osteoblasts, cementoblasts, and long bones (21, 22) . In addition, the proximal promoter of Osx can be activated by beta-catenin in in vitro luciferase assays and β-catenin directly binds the first intron of Osx in osteoblasts (21, 23) . Therefore, we wanted to determine if Osx is a downstream target of beta-catenin in the MD mesenchyme and possibly a contributing factor to the complete block in MD regression observed in males with MD mesenchyme knockout of beta-catenin. Reproductive tracts of Amhr2 Cre/+ ; Ctnnb1 flox/flox male embryos lack expression of beta-catenin in the MD mesenchyme and were examined at E14.5 for OSX expression by immunofluorescence. Amhr2 Cre/+ ; Ctnnb flox/flox male embryos expressed OSX protein in the MD mesenchyme at E14.5 ( Fig. 5 A, B) . Immunofluorescence of E14.5 male Osx Z/Z reproductive tracts lacked signal as expected and were used to confirm the specificity of the OSX antibody (data not shown). These results suggest that β-catenin is not required for the expression of OSX in the MD mesenchyme during male sex differentiation. Given that we established Osx is a downstream target of AMH signaling but not a direct target of known AMH effector beta-catenin we next analyzed the influence of Osx loss on MD regression in vivo.
MD regression is delayed in Osx null male mice
Osx null mice die at birth with severe skeletal defects (16) . However, MD regression is complete in males at the time of birth. To determine if Osx is required for MD regression we examined Osx Z/Z embryos at E15.5, E16.5, E17.5 and E18.5. At E15.5, the MD of Osx Z/+ and Osx Z/Z males are intact. Mullen 9 However, the Osx Z/+ MD is thinner than the Osx Z/Z MD, indicating a delay in MD regression in the Osx Z/Z males (data not shown). At E16.5, the MD of Osx Z/+ males have large gaps. However, the MD of Osx Z/Z males retain longer lengths of intact MD and fewer gaps are observed ( Fig. 6A, B) .
At E17.5, longer MD tissue remnants are observed near the testis in Osx Z/Z males in comparison to Osx Z/+ males (Fig. 6C, D) . At E18.5 Osx Z/Z males have a normal pattern of MD regression and the delay in MD regression defects is resolved. Other developmental delays or growth defects were not evident by gross examination of Osx null males (data not shown). This ~24-hour delay in MD regression was observed in all Osx null mutant males examined (n=3). This suggests that Osx contributes to MD regression. Osx has well-established roles in osteoblast, odontoblasts, and cementoblasts differentiation (16, 24) . However, this is the first evidence for Osx function in sex differentiation.
Discussion
We report on a novel AMH-induced gene, Osx, as a regulator of MD regression identified using a global unbiased approach. The identification of Osx in this process adds a key link to the gene expression network that may underlie MD regression. During development in skeletal bone and tooth, Osx has been demonstrated to be a key mesenchymal factor necessary for cell-fate decisions in the differentiation of specialized cells (16, 25) . To our knowledge ours is the first study implicating Osx as a factor in sex differentiation.
Osx is an important factor in bone homeostasis in adults and has roles in degradation of cartilage matrix by directly transcriptionally activing matrix metalloproteinase, Mmp13 (26) .
Further, in metastatic breast cancer, modulation of Osx levels results in a corresponding change in MMP-2 levels (27) . Two important processes in MD regression are the breakdown of the basement Mullen 10 membrane and apoptosis of MD epithelial cells. Secreted MMPs function to degrade extracellular matrix and also cleave signaling molecules to control multiple cellular processes including differentiation and apoptosis (28) . MMP-2 has been identified as a downstream target of AMH signaling and is expressed in a male-specific pattern in the MD during regression. Knockdown of Mmp2 using a morpholino and MMP inhibitors block MD regression in in vitro organ culture experiments (29) . However Mmp2 null male mice regress the MD, suggesting other MMPs may compensate for loss of MMP-2 (29) . MMP-14 is expressed in the reproductive tract during MD regression and may compensate for MMP-2 but its expression is not sexually dimorphically (29) .
Interestingly a female patient that lacks a uterus has been reported with a duplication in chromosome 14 containing the MMP14 gene region (30) . Considering that Osx modulates MMP expression in other systems, Osx may be contributing to MD regression by regulating MMP levels.
The AMH signaling pathway shares type one receptors, ACVRI and BMPR1A, and Runx2, Osx expression is upregulated by activated ΒETA-CATENIN in osteoblasts, cementoblasts, and long bones (21, 22) . In our previous study we found that β-catenin in the MD 
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It is also possible that SP family member Epfn/Sp6 is compensating for the loss of Osx during MD regression and allowing MD regression to proceed. There is high expression and log2 fold change of Epfn in male MD mesenchyme in our dataset. In addition, there is high homology of EPFN with OSX protein (46% identity match overall/ >90% identity match in DNA binding zinc finger domain) and sequence-based hierarchical clustering place Epfn and Osx within the same subfamily of SP proteins (31) . However, to our knowledge there is no previous evidence for overlapping function. Both Epfn and Osx have roles in tooth development but expression patterns are not overlapping with Osx expressed in dental mesenchyme and Epfn expressed in dental epithelial cells (25) . In the MD mesenchyme, both Epfn and Osx are expressed in males. The MD regression defects described have included complete and partial retention of MD derived tissues in postnatal and adult males and delayed regression that resolves at later embryonic stages. Factors whose loss results in no regression of the MD include Wnt7a (required for Amhr2 expression), Amh, Amhr2, Bmpr1a/Acvr2, Smad1,5,8, and β-catenin. With the exception of βcatenin all of these genes function in the initial activation of the AMH signaling pathway (2) .
Partial retention of MD-derived tissues has been associated with reductions in levels of AMH hormone and AMHR2, leading to AMH signaling below a threshold level needed for complete MD regression (32, 33) . Similarly, mice with lags in testis development and consequent delays in AMH secretion also exhibit deferred MD regression (34) . Partial retention of MD remnants was also observed in conditional knockout (CKO) in the MD mesenchyme of the TGF-β signaling pathway common Smad (co-Smad) Smad4. The defect in MD regression in the CKO Smad4 males is hypothesized to be caused by an observed reduction in β-catenin (35) . Interestingly constitutive activation of β-catenin in the MD mesenchyme resulted in a similar partial retention of MD tissues Mullen 13 in adult males (36) . To our knowledge the delay in MD regression in the Osx null males is the first described that is independent of AMH signaling levels and β-catenin expression.
Numerous studies have examined the consequences of gene mutations on MD regression in postnatal or adult males and considered any mutants without retained uterine tissue to have "normal" MD regression. This approach works well to identify factors required for activation of AMH signaling during MD regression such as Wnt7a, Amh and Amhr2 or early downstream effectors in the signaling cascade such as SMADs 1, 5, 8 (2) . However, monitoring mutant males for retained MD-derived tissues after MD regression is complete does not identify potential changes in the timing or process of MD regression. By examining Osx null mutant males at early time points during MD regression, we were able to identify a potential role for Osx in the initiation of MD regression that would have been missed if we had only examined newborn males.
Considering the results of this study, it may be of benefit to revisit candidate factors without postnatally retained uterine tissue at earlier time points during MD regression.
Materials and Methods
Mice
Ctnnb1 flox/flox mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA) and maintained on a C57BL/6J × 129X1/SvJ × 129S1/Sv mixed background (37) . Amhr2 tm3(Cre)Bhr (Amhr2-Cre; (20) ), Gt(ROSA)26Sor tm1(EYFP)Cos (R26R-YFP; (38) ), and Amhr2 tm2Bhr (Amhr2-lacZ; (18) ) were maintained on a C57BL/6J × 129/SvEv mixed background. Sp7 tm1Crm (Sp7-lacZ; (16)), and Mt-hAMH tg/+ (Mt-hAMH; (7) ) were maintained on a C57BL/6J congenic background. Amhr2-Cre, R26R-YFP, Amhr2-lacZ, Sp7-lacZ, Ctnnb1 flox/flox , and Mt-hAMH tg/+ mice were genotyped as previously described (7, 8, 16, 18, 37, 38) . The Institutional Animal Care and Use Committee of Bioinformatic analysis of transcriptomes RNA-seq data was mapped to the mouse genome with the bioinformatics tools Tophat and Bowtie using reference genome build NCBIM37 (13) . Ensembl annotation for the mouse genome was downloaded from the iGenome website (http://support.illumina.com/sequencing/sequencing_software/igenome.ilmn). Mapped RNA-seq data were then subject to differential expression analysis. Two bioinformatics tools were used for the analysis: Cufflink (13) and DESeq (14) . Cufflink uses mapped reads to generate a parsimonious set of transcripts, and then estimates the abundance of the transcripts (39) . DESeq utilizes the raw counts of mapped reads as data input and uses the negative binomial distribution model (14) . Using both methods, a list of genes with significant differential expression was obtained. To study the possible functions related to the changes of gene expression, pathway analysis was performed using Ingenuity Pathway Analysis tool from Ingenuity Systems (Ingenuity® Systems, www.ingenuity.com).
In situ hybridization
Embryos and reproductive tissues from neonates or adults were processed and section in situ hybridization was performed as previously described (10) . Osx RNA probe was generated from Mullen 16 plasmid pBSOsxBP containing a 560 bp fragment of mouse Osx (Osx transcript NM_1330458.4
bp 106-672) (16) .
X-gal staining
Embryos were collected at stages E13.5 to E18.5. Lower body trunks with urogenital tissues were isolated and processed for X-gal staining to visualize lacZ expression as described (18) .
Immunofluorescence
The following primary antibodies were used for immunofluorescence: Cytokeratin 8 (1:100;
Developmental Studies Hybridoma Bank; TROMA-I) and OSTERIX (1:50; a gift from Benoit de Crombrugghe) (16) . Immunofluorescence was performed as previously described (40) . At least 3 specimens of each genotype were analyzed for each staining. µm. Three or more of each genotype were observed for each developmental time point.
